Nektar Therapeutics

Schering Corporation

Nektar Therapeutics (india) Pvt. Ltd.

Seema Kantak

Deborah H Charych

Murali Krishna Addepalli

Steven Robert Lee

Toshihiko Takeuchi

Linda Masat

Sumant Ramachandra

Chin-Yi Huang

Chao Bai Huang

Walter Robert Bishop

The invention relates to (among other things) a method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) administering an IL-2R&#x3b2;-activating amount of a long acting, IL-2R&#x3b2;-selective agonist; and (b) administering a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.

Il-2R&#x3b2;-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

The invention relates to (among other things) method of administering to a patient suffering from a cancer, the method comprising the steps of: (a) an IL-2R&#x3b2;-activating amount of a long acting, IL-2R&#x3b2;-selective agonist; and (b) a CTLA-4 pathway-inhibiting amount of an anti-CTLA-4 antibody or a PD-1 pathway-inhibiting amount of an anti-PD-1 antibody.

IL-2R&#x3b2;-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Fully human anti-VEGF antibodies and methods of using

Growing community of inventors

Pacifica, CA, United States of America

Seema Kantak